Latest News by Industry
SAN DIEGO (AP) — SAN DIEGO (AP) — Mirati Therapeutics Inc. (MRTX) on Tuesday reported a loss of $202.5 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of $3.51.
The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $3.74 per share.
The biopharmaceutical company posted revenue of $934,000 in the period, missing Street forecasts. Six analysts surveyed by Zacks expected $3.8 million.
For the year, the company reported that its loss widened to $740.9 million, or $13.18 per share. Revenue was reported as $12.4 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a MRTX">Zacks stock report on MRTX at https://www.zacks.com/ap/MRTX